Pancreatic Cancer

Portada
Andrew M. Lowy, Steven D. Leach, Philip Philip
Springer Science & Business Media, 10 jul. 2008 - 744 páginas
0 Reseñas

Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important advances and outline areas of controversy and question in pancreatic cancer biology and treatment.

 

Comentarios de usuarios - Escribir una reseña

No hemos encontrado ninguna reseña en los lugares habituales.

Páginas seleccionadas

Índice

Spectrum of Human Pancreatic Neoplasia
3
Molecular Genetics of Pancreatic Cancer
27
Pancreatic Intraepithelial Neoplasia
41
Pathology and Molecular Biology of Intraductal Papillary Mucinous Neoplasms
52
Familial Pancreatic Cancer
65
Hereditary Pancreatitis and Pancreatic Cancer
81
Pancreatic Cancer Biology
97
Pancreatic Progenitor Cells in Injury and Regeneration
98
Surgical Management of IPMN
419
Palliation of Pancreatic Cancer
433
Cancer Pain and Symptom Management Drug Therapy
434
Supportive Care Cachexia Anorexia Syndrome
449
Endoscopic Palliation
463
Multimodality Therapy of Pancreatic Cancer
479
State of the Art in Radiation Therapy for Pancreas Cancer
480
The Evolution of Chemoradiation Strategies for Locally Advanced Pancreatic Cancer
497

Development of the Endocrine and Exocrine Pancreas
117
Models of Pancreatic Cancer Understanding Disease Progression
137
From Inception to Invasion Modeling Pathways to Pancreatic Cancer
159
Molecular Signaling Pathways in Pancreatic Cancer
180
Pancreatic Cancer Genomics Epigenomics and Proteomics
229
Pancreatic Cancer Staging
253
Imaging of Pancreatic Adenocarcinoma
255
The Role of PET Scanning in Pancreatic Cancer
271
Endoscopic Ultrasound Staging
284
Laparoscopic Staging
295
Surgery for Pancreatic Cancer
311
Pancreaticoduodenectomy Past and Present
313
Total Pancreatectomy for Treatment of Pancreatic Adenocarcinoma
328
Distal Pancreatectomy
341
Vascular Resection for Pancreatic Cancer
351
Complications of Pancreaticoduodenectomy
364
Controversies in the Surgical Management of Pancreatic Cancer
385
Laparoscopic Pancreatic Resections
401
Optimum Cytotoxic Therapy for Advanced Pancreatic Cancer
511
Adjuvant Chemoradiation for Pancreatic Cancer Past Present and Future
535
Neoadjuvant Treatment for Resectable and Locally Advanced Pancreatic Cancer
548
Emerging Targeted Therapies
563
An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer
565
Utility of Animal Models in Pancreatic Cancer Research
576
Kras Inhibitors and Pancreatic Cancer
601
HER Family of Receptors as Treatment Targets in Pancreatic Cancer
608
GSK3β Inhibition in Pancreatic Cancer
635
Inactivation of NFⲕB
647
Novel Targets for the Treatment of Pancreatic Cancer I Insulinlike Growth Factor Receptor
665
Novel Targets for the Treatment of Pancreatic Cancer II The Hedgehog Signaling Pathway
677
Development of Vaccine Therapy for Pancreas Cancer
683
Novel Approaches in Chemoradiation for Localized Pancreas Cancer
705
Incorporation of Genomics and Proteomics in Drug and Biomarker Development
713
Pitfalls in Clinical Trials and Future Directions
723
Index
733
Página de créditos

Otras ediciones - Ver todo

Términos y frases comunes

Pasajes populares

Página 39 - Bronner CE, Baker SM, Morrison PT et al. Mutation in the DNA mismatch repair gene homologue hMLHl is associated with hereditary non-polyposis colon cancer.
Página 36 - Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature (Lond.), 352: 345-347, 1991.

Información bibliográfica